2.86

1.38% -0.04

After Hours: 2.85 -0.010 -0.35%

Poseida Therapeutics Inc (PSTX)

Overview News Price History Option Chain Financials Discussions Forecast

Poseida Therapeutics Inc stock is traded at $2.86, with a volume of 1.48M. It is down -1.38% in the last 24 hours and up +0.00% over the past month. Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Previous Close:

$2.90

Open:

$2.6

24h Volume:

1.48M

Relative Volume:

3.25

Market Cap:

$270.52M

Revenue:

$64.70M

Net Income/Loss:

$-123.43M

P/E Ratio:

-11.92

EPS:

-0.24

Net Cash Flow:

$-95.23M

1W Performance:

-7.44%

1M Performance:

+0.00%

6M Performance:

-10.34%

1Y Performance:

+20.17%

1-Day Range:

$2.60

$2.915

1-Week Range:

$2.60

$3.15

52-Week Range:

$1.83

$4.27

Poseida Therapeutics Inc Stock (PSTX) Company Profile

Name

Poseida Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

858-779-3100

Address

9390 TOWNE CENTRE DRIVE, SAN DIEGO

Employee

337

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

PSTX's Discussions on Twitter

Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-04-23	Initiated	H.C. Wainwright	Buy
Jan-07-22	Initiated	Cantor Fitzgerald	Overweight
May-18-21	Initiated	BTIG Research	Buy
Aug-04-20	Initiated	BofA Securities	Buy
Aug-04-20	Initiated	Piper Sandler	Overweight
Aug-04-20	Initiated	William Blair	Outperform

View All

Poseida Therapeutics Inc Stock (PSTX) Latest News

12:18 PM

Poseida Therapeutics reveals promising trial results for myeloma treatment - Investing.com

12:18 PM

11:47 AM

Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement - Seeking Alpha

11:47 AM

10:36 AM

What technical indicators reveal about PSTX stock - US Post News

10:36 AM

09:56 AM

Metric Analysis: Poseida Therapeutics Inc (PSTX)’s Key Ratios in the Limelight - The Dwinnex

09:56 AM

05:22 AM

Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com UK

05:22 AM

Sep 27, 2024

Poseida Therapeutics Study of Prospective Myeloma Treatment Yields Positive Data - Marketscreener.com

Sep 27, 2024

Poseida reports high response in multiple myeloma trial - Investing.com

Sep 27, 2024

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients - PR Newswire

Sep 27, 2024

XTX Topco Ltd Increases Stock Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World

Sep 27, 2024

Sep 20, 2024

How did Poseida Therapeutics Inc (PSTX) fare last session? - US Post News

Sep 20, 2024

Pivotree (CVE:PVT) Shares Up 3% - Defense World

Sep 20, 2024

Sep 19, 2024

Provident Financial Services And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency

Sep 19, 2024

Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma - CGTLive™

Sep 19, 2024

Altrius Capital Management Inc Buys 15,174 Shares of POSCO Holdings Inc. (NYSE:PKX) - Defense World

Sep 19, 2024